AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT06299826
- Locations
- 🇸🇰
Research Site, Kosice, Slovakia
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C).
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Device: AeroChamber Plus Flow-Vu spacer
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT06297668
- Locations
- 🇩🇪
Research Site, Berlin, Germany
REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma
Terminated
- Conditions
- Asthma, Bronchial
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT06299306
- Locations
- 🇩🇪
Research Site, Weissenburg, Germany
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Phase 3
Recruiting
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Drug: BGF MDI 320/14.4/9.6 μgDrug: GFF MDI 14.4/9.6 μg
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT06283966
- Locations
- 🇬🇧
Research Site, Witney, United Kingdom
PROPE Severe Asthma Study in Egypt
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 201
- Registration Number
- NCT06283290
- Locations
- 🇪🇬
Research Site, Sharkia, Egypt
C.Difficile Observational Study
Completed
- Conditions
- Clostridium Infections
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT06277999
- Locations
- 🇺🇸
Research Site, Charlottesville, Virginia, United States
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT06271837
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
🇨🇳Research Site, Zhengzhou, China
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Phase 2
Completed
- Conditions
- Liver Cirrhosis
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT06269484
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Phase 3
Recruiting
- Conditions
- Chronic Kidney Disease and Hypertension
- Interventions
- Drug: Baxdrostat/dapagliflozin
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT06268873
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
Study of AZD0754 in Participants With Metastatic Prostate Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06267729
- Locations
- 🇦🇺
Research Site, East Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath